BOSTON, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics (VERV), a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today reported pipeline updates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results